Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 7 |
List of Tables | 7 | 1 |
List of Figures | 8 | 1 |
Introduction | 9 | 1 |
Global Markets Direct Report Coverage | 9 | 1 |
Tetanus Overview | 10 | 1 |
Therapeutics Development | 11 | 2 |
Pipeline Products for Tetanus Overview | 11 | 1 |
Pipeline Products for Tetanus Comparative Analysis | 12 | 1 |
Tetanus Therapeutics under Development by Companies | 13 | 2 |
Tetanus Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
Tetanus Pipeline Products Glance | 16 | 3 |
Late Stage Products | 16 | 1 |
Clinical Stage Products | 17 | 1 |
Early Stage Products | 18 | 1 |
Tetanus Products under Development by Companies | 19 | 2 |
Tetanus Products under Investigation by Universities/Institutes | 21 | 1 |
Tetanus Companies Involved in Therapeutics Development | 22 | 17 |
Beijing Minhai Biotechnology Co., Ltd | 22 | 1 |
Bharat Biotech International Limited | 23 | 1 |
BioClonetics Immunotherapeutics, Inc. | 24 | 1 |
Biological E. Limited | 25 | 1 |
Boryung Pharmaceutical Co., Ltd. | 26 | 1 |
Daiichi Sankyo Company, Limited | 27 | 1 |
GlaxoSmithKline Plc | 28 | 1 |
Green Cross Corporation | 29 | 1 |
Indian Immunologicals Limited | 30 | 1 |
Kaketsuken K.K. | 31 | 1 |
LG Life Science LTD. | 32 | 1 |
Panacea Biotec Limited | 33 | 1 |
Prometheon Pharma, LLC | 34 | 1 |
Sanofi Pasteur SA | 35 | 1 |
Serum Institute of India Limited | 36 | 1 |
Sinovac Biotech Ltd. | 37 | 1 |
Zydus Cadila Healthcare Limited | 38 | 1 |
Tetanus Therapeutics Assessment | 39 | 8 |
Assessment by Monotherapy Products | 39 | 1 |
Assessment by Combination Products | 40 | 1 |
Assessment by Target | 41 | 2 |
Assessment by Route of Administration | 43 | 2 |
Assessment by Molecule Type | 45 | 2 |
Drug Profiles | 47 | 39 |
(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine Drug Profile | 47 | 1 |
(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine Drug Profile | 48 | 1 |
(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine Drug Profile | 49 | 1 |
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine Drug Profile | 50 | 1 |
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine Drug Profile | 51 | 1 |
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine Drug Profile | 52 | 1 |
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine Drug Profile | 53 | 1 |
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine Drug Profile | 54 | 1 |
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine Drug Profile | 55 | 1 |
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine Drug Profile | 56 | 1 |
(diphtheria + pertussis (acellular) + poliovirus + tetanus) vaccine Drug Profile | 57 | 1 |
(diphtheria + pertussis (acellular) + tetanus) vaccine Drug Profile | 58 | 1 |
(diphtheria + pertussis (acellular) + tetanus) vaccine Drug Profile | 59 | 1 |
(diphtheria + pertussis (acellular) + tetanus) vaccine Drug Profile | 60 | 1 |
(diphtheria + pertussis (acellular) + tetanus) vaccine Drug Profile | 61 | 1 |
(diphtheria + pertussis (acellular) + tetanus) vaccine Drug Profile | 62 | 1 |
(diphtheria + pertussis (acellular) + tetanus) vaccine 1 Drug Profile | 63 | 1 |
(diphtheria + pertussis (acellular) + tetanus) vaccine 2 Drug Profile | 64 | 1 |
(diphtheria + pertussis (whole cell) + tetanus) vaccine Drug Profile | 65 | 1 |
(diphtheria + pertussis (whole-cell) + tetanus) vaccine Drug Profile | 66 | 1 |
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine Drug Profile | 67 | 2 |
(diphtheria + tetanus + pertussis (acellular)) vaccine Drug Profile | 69 | 1 |
(diphtheria + tetanus) vaccine Drug Profile | 70 | 1 |
diphtheria + pertussis(acellular) + tetanus vaccine Drug Profile | 71 | 1 |
Eupenta Drug Profile | 72 | 1 |
GC-1107 Drug Profile | 73 | 1 |
GC-3111A Drug Profile | 74 | 1 |
KD-370 Drug Profile | 75 | 1 |
LBVD Drug Profile | 76 | 1 |
Monoclonal Antibody for Tetanus Drug Profile | 77 | 1 |
Monoclonal Antibody for Tetanus Drug Profile | 78 | 1 |
Monoclonal Antibody to Target Tetanus Toxin for Tetanus Drug Profile | 79 | 1 |
tetanus vaccine Drug Profile | 80 | 1 |
tetanus vaccine Drug Profile | 81 | 1 |
tetanus vaccine Drug Profile | 82 | 1 |
tetanus vaccine Drug Profile | 83 | 1 |
VN-0103 Drug Profile | 84 | 1 |
VN-0105 Drug Profile | 85 | 1 |
Tetanus Dormant Projects | 86 | 2 |
Tetanus Discontinued Products | 88 | 1 |
Tetanus Product Development Milestones | 89 | 10 |
Featured News &Press Releases | 89 | 1 |
Apr 01, 2015: LG Life Sciences Succeeds in Phase 3 International Clinical Trials for 5-in-1 Vaccine Eupenta | 89 | 1 |
Nov 24, 2014: CanSinotech submitted CTA of Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed to CFDA | 89 | 1 |
Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur s Investigational Pediatric Hexavalent Vaccine | 89 | 1 |
Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel Tdap Vaccine to Include Persons 10 Years of Age | 90 | 1 |
Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima | 91 | 1 |
Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine | 92 | 1 |
Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets | 92 | 1 |
Jun 22, 2012: Sanofi Pasteur s Hexaxim Receives Positive Opinion From European Medicines Agency | 93 | 1 |
Mar 13, 2008: U.S. FDA Licenses DAPTACEL Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series | 94 | 1 |
Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis | 95 | 1 |
Jun 13, 2005: U.S. FDA Licenses sanofi Pasteur s ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis | 95 | 1 |
Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine | 96 | 1 |
Mar 18, 2005: FDA Advisory Panel Recommends Licensure of sanofi pasteur s ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis | 96 | 1 |
Aug 11, 2004: Aventis Submits Application for FDA Licensure of ADACEL Vaccine for Prevention of Tetanus, Diphtheria and Pertussis in Adolescents and Adults. | 97 | 1 |
May 14, 2002: Food and Drug Administration Approval of a Fifth Acellular Pertussis Vaccine for Use Among Infants and Young Children | 98 | 1 |
Appendix | 99 | 2 |
Methodology | 99 | 1 |
Coverage | 99 | 1 |
Secondary Research | 99 | 1 |
Primary Research | 99 | 1 |
Expert Panel Validation | 99 | 1 |
Contact Us | 99 | 1 |
Disclaimer | 100 | 1 |